The safety of novel drugs used to treat irritable bowel syndrome

Bibliography

• Ding Y, Lu B, Chen D, et al. Proteomic analysis of colonic mucosa in a rat model of irritable bowel syndrome. Proteomics 2010;10:2620-30
   PubMed Web of Science ®Google Scholar
• Mozaffari S, Rahimi R, Abdollahi M. Implications of melatonin therapy in irritable bowel syndrome: a systematic review. Curr Pharm Des 2010;16:3646-55
   PubMed Web of Science ®Google Scholar
• Liebregts T, Adam B, Bredack C, et al. Immune activation in patients with irritable bowel syndrome. Gastroenterology 2007;132:913-20
   PubMed Web of Science ®Google Scholar
• Ford AC, Talley NJ, Spiegel BMR, et al. Effect of fiber, antispasmodics, and peppermint oil in irritable bowel syndrome: systematic review and meta-analysis. Br Med J 2008;337:1388-92
   Google Scholar
• Rahimi R, Nikfar S, Rezaie A, Abdollahi M. Efficacy of tricyclic antidepressants in irritable bowel syndrome: a meta-analysis. World J Gastroenterol 2009;15:1548-53
   PubMed Web of Science ®Google Scholar
• Rahimi R, Nikfar S, Abdollahi M. Selective serotonin reuptake inhibitors for the management of irritable bowel syndrome: a meta-analysis of randomized controlled trials. Arch Med Sci 2008;4:71-6
   Web of Science ®Google Scholar
• Sainsbury A, Ford AC. Treatment of irritable bowel syndrome: beyond fiber and antispasmodic agents. Therap Adv Gastroenterol 2011;4:115-27
   PubMedGoogle Scholar
• Nikfar S, Rahimi R, Rahimi F, et al. Efficacy of probiotics in irritable bowel syndrome: a meta-analysis of randomized, controlled trials. Dis Colon Rectum 2008;51:1775-80
   PubMed Web of Science ®Google Scholar
• Hosseini A, Nikfar S, Abdollahi M. Probiotics use to treat irritable bowel syndrome. Expert Opin Biol Ther 2012;12:1323-34
   PubMed Web of Science ®Google Scholar
• Rezaie A, Nikfar S, Abdollahi M. The place of antibiotics in management of irritable bowel syndrome: a systematic review and meta-analysis. Arch Med Sci 2010;6:49-55
   PubMed Web of Science ®Google Scholar
• Rahimi R, Nikfar S, Abdollahi M. Efficacy and tolerability of alosetron for the treatment of irritable bowel syndrome in women and men: a meta-analysis of eight randomized, placebo-controlled, 12-week trials. Clin Ther 2008;30:884-901
   PubMed Web of Science ®Google Scholar
• Atkinson W, Lockhart S, Whorwell PJ, et al. Altered 5-hydroxytryptamine signaling in patients with constipation and diarrhea-predominant irritable bowel syndrome. Gastroenterology 2006;130:34-43
   PubMed Web of Science ®Google Scholar
• Rahimi R, Abdollahi M. Herbal medicines for the management of irritable bowel syndrome: a comprehensive review. World J Gastroenterol 2012;18:589-600
   PubMed Web of Science ®Google Scholar
• Asadi-Shahmirzadi A, Mozaffari S, Sanei Y, et al. Benefit of Aloe vera and Matricaria recutita mixture in rat irritable bowel syndrome: combination of antioxidant and spasmolytic effects. Chin J Integr Med 2012. [Epub ahead of print]
   PubMedGoogle Scholar
• Mozaffari S, Esmaily H, Rahimi R, et al. Effects of Hypericum perforatum extract on rat irritable bowel syndrome. Pharmacogn Mag 2011;7:213-23
   PubMed Web of Science ®Google Scholar
• Mozaffari S, Nikfar S, Abdollahi M. Systematic review/meta-analysisefficacy and tolerability of renzapride in irritable bowel syndrome: a meta-analysis of randomized, controlled clinical trials including 2528 patients. Arch Med Sci 2014;10:10-18
   PubMed Web of Science ®Google Scholar
• Mozaffari S, Nikfar S, Abdollahi M. Metabolic and toxicological considerations for the latest drugs used to treat irritable bowel syndrome. Expert Opin Drug Metab Toxicol 2013;9:403-21
   PubMed Web of Science ®Google Scholar
• Fukudo S, Hongo M, Kaneko H, Ueno R. Efficacy and safety of oral lubiprostone in constipated patients with or without irritable bowel syndrome: a randomized, placebo-controlled and dose-finding study. Neurogastroenterol Motil 2011;23:544-e205
   PubMed Web of Science ®Google Scholar
• Drossman DA, Chey WD, Johanson JF, et al. Clinical trial: lubiprostone in patients with constipation-associated irritable bowel syndrome – results of two randomized, placebo-controlled studies. Aliment Pharmacol Ther 2009;29:329-41
   PubMed Web of Science ®Google Scholar
• Chamberlain SM, Rao SS. Safety evaluation of lubiprostone in the treatment of constipation and irritable bowel syndrome. Expert Opin Drug Saf 2012;11:841-50
   PubMed Web of Science ®Google Scholar
• Camilleri M, Bharucha AE, Ueno R, et al. Effect of a selective chloride channel activator, lubiprostone, on gastrointestinal transit, gastric sensory, and motor functions in healthy volunteers. Am J Physiol Gastrointest Liver Physiol 2006;290:G942-7
   PubMed Web of Science ®Google Scholar
• Chey WD, Drossman DA, Johanson JF, et al. Safety and patient outcomes with lubiprostone for up to 52 weeks in patients with irritable bowel syndrome with constipation. Aliment Pharmacol Ther 2012;35:587-99
   PubMed Web of Science ®Google Scholar
• Johanson JF, Drossman DA, Panas R, et al. Clinical trial: phase 2 study of lubiprostone for irritable bowel syndrome with constipation. Aliment Pharmacol Ther 2008;27:685-96
   PubMed Web of Science ®Google Scholar
• Johanson JF, Morton D, Geenen J, Ueno R. Multicenter, 4-week, double-blind, randomized, placebo-controlled trial of lubiprostone, a locally-acting type-2 chloride channel activator, in patients with chronic constipation. Am J Gastroenterol 2008;103:170-7
   PubMed Web of Science ®Google Scholar
• Efficacy and Safety of Lubiprostone in Patients With Irritable Bowel Syndrome With Constipation. Sucampo Pharmaceuticals, Inc. 2006. Available from: http://www.clinicaltrial.gov/ct2/show/record/NCT00399542?term=NCT+00399542&rank=1
   Google Scholar
• Lembo AJ, Johanson JF, Parkman HP, et al. Long-term safety and effectiveness of lubiprostone, a chloride channel (ClC-2) activator, in patients with chronic idiopathic constipation. Dig Dis Sci 2011;56:2639-45
   PubMed Web of Science ®Google Scholar
• Sherid M, Sifuentes H, Samo S, et al. Lubiprostone induced ischemic colitis. World J Gastroenterol 2013;19:299-303
   PubMed Web of Science ®Google Scholar
• Hyman PE, Di Lorenzo C, Prestridge LL, et al. An open-label, multicenter, safety and effectiveness study of lubiprostone for the treatment of functional constipation in children. J Pediatr Gastroenterol Nutr 2013. [Epub ahead of print]
   Web of Science ®Google Scholar
• Lee N, Wald A. The pharmacokinetics, pharmacodynamics, clinical efficacy, safety and tolerability of linaclotide. Expert Opin Drug Metab Toxicol 2011;7:651-9
   PubMed Web of Science ®Google Scholar
• Lembo AJ, Kurtz CB, Macdougall JE, et al. Efficacy of linaclotide for patients with chronic constipation. Gastroenterology 2010;138:886-95
   PubMed Web of Science ®Google Scholar
• Lembo AJ, Schneier HA, Shiff SJ, et al. Two randomized trials of linaclotide for chronic constipation. N Engl J Med 2011;365:527-36
   PubMed Web of Science ®Google Scholar
• Andresen V, Camilleri M, Busciglio IA, et al. Effect of 5 days linaclotide on transit and bowel function in females with constipation-predominant irritable bowel syndrome. Gastroenterology 2007;133:761-8
   PubMed Web of Science ®Google Scholar
• Rao S, Lembo AJ, Shiff SJ, et al. A 12-week, randomized, controlled trial with a 4-week randomized withdrawal period to evaluate the efficacy and safety of linaclotide in irritable bowel syndrome with constipation. Am J Gastroenterol 2012;107:1714-24
   PubMed Web of Science ®Google Scholar
• Currie MG, Kurtz CB, Mahajan-Miklos S, et al. Effects of a single dose administration of MD-1100 on safety, tolerability, exposure, and stool consistency in healthy subjects. Am J Gastoenterol 2005;100:S328
   Web of Science ®Google Scholar
• Kurtz CB, Fitch D, Busby RW, et al. Effects of multidose administration of MD-1100 on safety, tolerability, exposure, and pharmacodynamics in healthy subjects. Gastroenterology 2006;130:A26
   PubMed Web of Science ®Google Scholar
• Johnston JM, Kurtz CB, Macdougall JE, et al. Linaclotide improves abdominal pain and bowel habits in a phase IIb study of patients with irritable bowel syndrome with constipation. Gastroenterology 2010;139:1877-86
   PubMed Web of Science ®Google Scholar
• Chey WD, Lembo AJ, Lavins BJ, et al. Linaclotide for irritable bowel syndrome with constipation: a 26-week, randomized, double-blind, placebo-controlled trial to evaluate efficacy and safety. Am J Gastroenterol 2012;107:1702-12
   PubMed Web of Science ®Google Scholar
• An Open-Label, Long-Term Safety Study of Linaclotide in Patients With Chronic Constipation or Irritable Bowel Syndrome With Constipation. Forest Laboratories. 2008. Available from: http://www.clinicaltrial.gov/ct2/show/NCT00765999?term=NCT00765999&rank=1
   Google Scholar
• An Open-label, Long-term Safety Study of Linaclotide in Patients With Chronic Constipation or Irritable Bowel Syndrome With Constipation. Ironwood Pharmaceuticals, Inc. 2008. Available from: http://www.clinicaltrial.gov/ct2/show/NCT00730171?term=NCT00730171&rank=1
   Google Scholar
• Corsetti M, Tack J. Linaclotide: a new drug for the treatment of chronic constipation and irritable bowel syndrome with constipation. United Eur Gastroenterol J 2013;1:7-20
   PubMed Web of Science ®Google Scholar
• Delvaux M, Beck A, Jacob J, et al. Effect of asimadoline, a kappa opioid agonist, on pain induced by colonic distension in patients with irritable bowel syndrome. Aliment Pharmacol Ther 2004;20:237-46
   PubMed Web of Science ®Google Scholar
• Mangel AW, Bornstein JD, Hamm LR, et al. Clinical trial: asimadoline in the treatment of patients with irritable bowel syndrome. Aliment Pharmacol Ther 2008;28:239-49
   PubMed Web of Science ®Google Scholar
• Kramer HJ, Uhl W, Ladstetter B, Bäcker A. Influence of asimadoline, a new kappa-opioid receptor agonist, on tubular water absorption and vasopressin secretion in man. Br J Clin Pharmacol 2000;50:227-35
   PubMed Web of Science ®Google Scholar
• Delgado-Aros S, Chial HJ, Cremonini F, et al. Effects of asimadoline, a kappa-opioid agonist, on satiation and postprandial symptoms in health. Aliment Pharmacol Ther 2003;18:507-14
   PubMed Web of Science ®Google Scholar
• Szarka LA, Camilleri M, Burton D, et al. Efficacy of on-demand asimadoline, a peripheral kappa-opioid agonist, in females with irritable bowel syndrome. Clin Gastroenterol Hepatol 2007;5:1268-75
   PubMed Web of Science ®Google Scholar
• Talley NJ, Choung RS, Camilleri M, et al. Asimadoline, a kappa-opioid agonist, and satiation in functional dyspepsia. Aliment Pharmacol Ther 2008;27:1122-31
   PubMed Web of Science ®Google Scholar
• Asimadoline for the Treatment of Post-Operative Ileus. Tioga Pharmaceuticals. 2007. Available from: http://www.clinicaltrial.gov/ct2/show/NCT00443040?term=%28NCT00443040%29&rank=1
   Google Scholar
• Mangel AW, Hicks GA. Asimadoline and its potential for the treatment of diarrhea-predominant irritable bowel syndrome: a review. Clin Exp Gastroenterol 2012;5:1-10
   Google Scholar
• Kadokura T, den Adel M, Krauwinkel WJ, et al. The effect of fluvoxamine on the pharmacokinetics, safety, and tolerability of ramosetron in healthy subjects. Eur J Clin Pharmacol 2008;64:691-5
   PubMed Web of Science ®Google Scholar
• Lee KJ, Kim NY, Kwon JK, et al. Efficacy of ramosetron in the treatment of male patients with irritable bowel syndrome with diarrhea: a multicenter, randomized clinical trial, compared with mebeverine. Neurogastroenterol Motil 2011;23:1098-104
   PubMed Web of Science ®Google Scholar
• Matsueda K, Harasawa S, Hongo M, et al. A phase II trial of the novel serotonin type 3 receptor antagonist ramosetron in Japanese male and female patients with diarrhea-predominant irritable bowel syndrome. Digestion 2008;77:225-35
   PubMed Web of Science ®Google Scholar
• Matsueda K, Harasawa S, Hongo M, et al. A randomized, double-blind, placebo-controlled clinical trial of the effectiveness of the novel serotonin type 3 receptor antagonist ramosetron in both male and female Japanese patients with diarrhea-predominant irritable bowel syndrome. Scand J Gastroenterol 2008;43:1202-11
   PubMed Web of Science ®Google Scholar
• Matsueda K, Arakawa T, Matsumoto T, Sasaki D. Long-term study of YM060 (ramosetron hydrochloride) in Japanese patients (male) with diarrhea-predominant irritable bowel syndrome. Rinsho Iyaku 2008;24:655-78
   Google Scholar
• Descombe JJ, Dubourg D, Picard M, Palazzini E. Pharmacokinetic study of rifaximin after oral administration in healthy volunteers. Int J Clin Pharmacol Res 1994;14:51-6
   PubMedGoogle Scholar
• Menees SB, Maneerattannaporn M, Kim HM, Chey WD. The efficacy and safety of rifaximin for the irritable bowel syndrome: a systematic review and meta-analysis. Am J Gastroenterol 2012;107:28-35
   PubMed Web of Science ®Google Scholar
• Pimentel M, Lembo A, Chey WD, et al. Rifaximin therapy for patients with irritable bowel syndrome without constipation. N Engl J Med 2011;364:22-32
   PubMed Web of Science ®Google Scholar
• Sharara AI, Aoun E, Abdul-Baki H, et al. A randomized double-blind placebo controlled trial of rifaximin in patients with abdominal bloating and flatulence. Am J Gastroenterol 2006;101:326-33
   PubMed Web of Science ®Google Scholar
• Lembo AZ, Ferreira SF, Ringel Nl, et al. Rifaximin for the treatment of diarrhea-associated irritable bowel syndrome: short term treatment leading to long term sustained response. Gastroenterology 2008;134:P-255
   Google Scholar
• Scarpellini E, Giorgio V, Gabrielli M, et al. Rifaximin treatment for small intestinal bacterial overgrowth in children with irritable bowel syndrome. Eur Rev Med Pharmacol Sci 2013;17:1314-20
   PubMed Web of Science ®Google Scholar
• Meyers NL, Hickling RI. Pharmacology and metabolism of renzapride: a novel therapeutic agent for the potential treatment of irritable bowel syndrome. Drugs R D 2008;9:37-63
   PubMed Web of Science ®Google Scholar
• Tack J, Middleton SJ, Horne MC, et al. Pilot study of the efficacy of renzapride on gastrointestinal motility and symptoms in patients with constipation-predominant irritable bowel syndrome. Aliment Pharmacol Ther 2006;23:1655-65
   PubMed Web of Science ®Google Scholar
• Camilleri M, McKinzie S, Fox J, et al. Effect of renzapride on transit in constipation-predominant irritable bowel syndrome. Clin Gastroenterol Hepatol 2004;2:895-904
   PubMed Web of Science ®Google Scholar
• Spiller RC, Meyers NL, Hickling RI. Identification of patients with non-d, non-C irritable bowel syndrome and treatment with renzapride: an exploratory, multicenter, randomized, double-blind, placebo-controlled clinical trial. Dig Dis Sci 2008;53:3191-200
   PubMed Web of Science ®Google Scholar
• Lembo AJ, Cremonini F, Meyers N, Hickling R. Clinical trial: renzapride treatment of women with irritable bowel syndrome and constipation – a double-blind, randomized, placebo-controlled, study. Aliment Pharmacol Ther 2010;31:979-90
   PubMed Web of Science ®Google Scholar
• George AM, Meyers NL, Hickling RI. Clinical trial: renzapride therapy for constipation-predominant irritable bowel syndrome – multicentre, randomized, placebo-controlled, double-blind study in primary healthcare setting. Aliment Pharmacol Ther 2008;27:830-7
   PubMed Web of Science ®Google Scholar
• Ford AC, Brandt LJ, Young C, et al. Efficacy of 5-HT3 antagonists and 5-HT4 agonists in irritable bowel syndrome: systematic review and meta-analysis. Am J Gastroenterol 2009;104:1831-43
   PubMed Web of Science ®Google Scholar
• Meyers NL, Hickling RI. The cardiovascular safety profile of renzapride, a novel treatment for irritable bowel syndrome. J Int Med Res 2007;35:848-66
   PubMed Web of Science ®Google Scholar
• Meyers NL, Tack J, Middleton SJ, et al. Efficacy and safety of renzapride in patients with constipation-predominant irritable bowel syndrome. Gut 2002;51(SIII):A10
   Google Scholar
• George A, Meyers NL, Palmer RMJ. Efficacy and safety of renzapride in constipation-predominant IBS: a phase IIb study in the UK primary healthcare setting. Gut 2003;52(SVI):A91
   PubMedGoogle Scholar
• Gras-Miralles B, Cremonini F. A critical appraisal of lubiprostone in the treatment of chronic constipation in the elderly. Clin Interv Aging 2013;8:191-200
   PubMed Web of Science ®Google Scholar
• Shah E, Kim S, Chong K, et al. Evaluation of harm in the pharmacotherapy of irritable bowel syndrome. Am J Med 2012;125:381-93
   PubMed Web of Science ®Google Scholar
• Wensel TM, Luthin DR. Linaclotide: a novel approach to the treatment of irritable bowel syndrome. Ann Pharmacother 2011;45:1535-43
   PubMed Web of Science ®Google Scholar
• Quigley EM, Tack J, Chey WD, et al. Randomised clinical trials: linaclotide phase 3 studies in IBS-C - a prespecified further analysis based on European Medicines Agency-specified endpoints. Aliment Pharmacol Ther 2013;37:49-61
   PubMed Web of Science ®Google Scholar
• Gale JD. The use of novel promotility and prosecretory agents for the treatment of chronic idiopathic constipation and irritable bowel syndrome with constipation. Adv Ther 2009;26:519-30
   PubMed Web of Science ®Google Scholar